Engineered T Cells for Adoptive Therapy

Sunday, 16 February 2014
Columbus CD (Hyatt Regency Chicago)
Carl June , Abramson Family Cancer Research Institute, Philadelphia, PA
Cell therapy with engineered T lymphocytes has shown promising results in early clinical trials in patients with hematologic malignancies. This presentation will review a brief history of these trials as well as discuss some of the limitations of this type of therapy. The presentation will end with mention of ongoing and proposed trials for cell-based immunotherapies for cancer.